GPs are now able to prescribe Duodart for symptomatic benign prostatic hyperplasia
GPs are now able to prescribe the dutasteride–tamsulosin combination (Duodart) for symptomatic benign prostatic hyperplasia.
As of June 1, the PBS will no longer require a urologist to initiate the medication, meaning GPs could prescribe the medication only by private script.
The combination was PBS listed in 2011, but a recent Drug Utilisation Sub-Committee (DUSC) review concluded it was being substantially underutilised.
“DUSC considered that the PBS restriction for initiation by a urologist may be limiting patient access to these medicines,” they wrote.
The group suggested that the PBAC consider changing the restriction to allow for wider prescribing.
“This is an important development, especially for men in regional and remote Australia, who have specific challenges in accessing healthcare professionals,” Professor Simon Willcock, director of Primary Care Services at Macquarie University Hospital, said in a statement.
“Overall I think this change will help men who are not engaged with a specialist to receive effective treatment for BPH by consulting with their GP,” Professor Willcock said.
“Anything we can do to smooth the path to effective treatment for BPH in men who have this condition is a positive move.”
Also backing the move was Sydney urologist Associate Professor Manish Patel. “Clearly there will still be cases where the GP considers referral to a specialist as the appropriate treatment path. But in cases where the diagnosis is clear, GPs will be able to initiate treatment. I think overall this is a positive development,” Professor Patel said.
